<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002272</url>
  </required_header>
  <id_info>
    <org_study_id>020G</org_study_id>
    <secondary_id>89-FOS-09B</secondary_id>
    <nct_id>NCT00002272</nct_id>
  </id_info>
  <brief_title>An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies</brief_title>
  <official_title>An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astra USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of intermittent intravenous (IV) foscarnet in the&#xD;
      treatment of acyclovir-resistant herpes simplex virus (HSV) infections in AIDS patients and&#xD;
      other immunocompromised patients. To evaluate the necessity, efficacy, and safety of IV&#xD;
      maintenance foscarnet therapy in preventing recurrent disease. To confirm the&#xD;
      pharmacokinetics of intermittent induction and maintenance IV regimens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Herpes Simplex</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foscarnet sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Cyclosporine.&#xD;
&#xD;
        Patients must have AIDS as defined by the CDC, or be patients with other immunocompromised&#xD;
        states (transplant patients; other hematologic malignancies with recognized cell-mediated&#xD;
        immune deficiency), and have herpes simplex virus (HSV) infection documented by culture and&#xD;
        in vitro resistance to acyclovir by standard laboratory susceptibility or suspected&#xD;
        resistance to acyclovir after an acyclovir treatment failure in which acyclovir was&#xD;
        administered for at least 2 weeks intravenously at doses of 30 mg/kg/day (or a comparative&#xD;
        dose adjusted for renal insufficiency). In vitro susceptibility data must be pending in the&#xD;
        latter case.&#xD;
&#xD;
          -  Patients must be able to give informed consent.&#xD;
&#xD;
          -  Patients &lt; 18 years of age may participate with the consent of parent, guardian, or&#xD;
             person with power of attorney, or through the provisions of state laws regarding&#xD;
             emancipated minors.&#xD;
&#xD;
          -  Expected survival of at least 6 months.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Cyclosporine.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Known allergy to foscarnet.&#xD;
&#xD;
          -  Any clinically significant pulmonary or neurologic impairment (e.g., patients who are&#xD;
             intubated or comatose).&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any potentially nephrotoxic agent (except cyclosporine).&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Biologic response modifiers.&#xD;
&#xD;
          -  Investigational agents.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Known allergy to foscarnet.&#xD;
&#xD;
          -  Any clinically significant pulmonary or neurologic impairment (e.g., patients who are&#xD;
             intubated or comatose).&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 7 days of entry:&#xD;
&#xD;
          -  Any potentially nephrotoxic agent (except cyclosporine).&#xD;
&#xD;
          -  Excluded within 14 days of entry:&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Biologic response modifiers.&#xD;
&#xD;
          -  Investigational agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Foscarnet Research Program / Park Plaza Hosp</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Balfour HH Jr, Benson C, Braun J, Cassens B, Erice A, Friedman-Kien A, Klein T, Polsky B, Safrin S. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr (1988). 1994 Mar;7(3):254-60.</citation>
    <PMID>8106965</PMID>
  </reference>
  <verification_date>September 1990</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Immune Tolerance</keyword>
  <keyword>Injections, Intravenous</keyword>
  <keyword>Herpes Simplex</keyword>
  <keyword>Immunity, Cellular</keyword>
  <keyword>Drug Resistance</keyword>
  <keyword>Foscarnet</keyword>
  <keyword>Acyclovir</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foscarnet</mesh_term>
    <mesh_term>Phosphonoacetic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

